Embera NeuroTherapeutics, Inc. Forms Clinical Development Collaboration with Exponential Pharma Ventures

SHREVEPORT, La.--(BUSINESS WIRE)--Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for drug dependence, smoking cessation and obesity, announced today that the company has retained Exponential Pharma Ventures LLC to assist in establishing a clinical development partnership for its cocaine dependence program with a fully integrated pharmaceutical company. Exponential Pharma Ventures, a company specialized in development of early stage biomedical technology through pharmaceutical partnerships, is seeking a partner to advance Embera’s lead product, EMB-001C into phase 2a clinical trials. The pharmaceutical partner will receive an option to license and commercialize the product after clinical proof of concept. Embera and Exponential have already initiated discussions with prospective partners. EMB-001C is a combination drug product that has recently demonstrated preliminary clinical proof of concept in a randomized, double-blind, placebo–controlled pilot study in cocaine-dependent human subjects.